Kyverna Therapeutics (KYTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Kyverna Therapeutics (KYTX) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.00 of bullish evidence against -0.27 bearish.

Kyverna Therapeutics last closed at $6.32, +1.61% on the session.

Against the IVW growth benchmark the position is +0.69% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

16 graded predictions for KYTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Kyverna Therapeutics in the 13th percentile on return on equity, where 100 is best.

Kyverna Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $384.66M.

StockMap tracks Kyverna Therapeutics as the 182nd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Kyverna Therapeutics ranks 234th of 344 in the group, against a group median of -0.21.